Cancer Drug

• The FDA has expanded its approval of a Bayer lung cancer drug, although the specific details of the expansion are not provided in the given information. • The announcement is part of a broader set of biotech news that includes updates on UniQure and an AI effort to manage heart failure. • The expansion of the Bayer lung cancer drug approval may improve treatment options for patients with lung cancer, potentially leading to better health outcomes.

• A new wave of illegal fruity vapes has emerged, posing health risks to users, particularly among youth and young adults. • Researchers and healthcare providers are noting an increasing trend of children being prescribed GLP-1s, a type of medication typically used to treat type 2 diabetes and obesity. • The emergence of these health issues and the growing need for effective treatments, such as the pancreatic cancer drug RevMed, highlights the importance of continued research and development in the healthcare sector.

• The FDA approved Rasonque, a new pancreatic cancer drug developed by Revolution Medicines. • Patients seeking the treatment have found that insurance coverage can take several weeks to catch up with the official approval. • This delay prevents eligible patients from accessing a breakthrough medication during a critical window of their illness.

• The White House is finalizing drug pricing agreements with pharmaceutical companies Bayer, Takeda, and CSL Behring. • These deals are part of a broader initiative by the U.S. government to secure more affordable medication costs through direct negotiations with drugmakers. • The news coincides with the approval of a new cancer therapy, highlighting a period of significant regulatory and financial shifts in the pharma industry.

• On August 31, 2026, the FDA granted expedited approval to daraxonrasib (marketed as Rasonque), a first-of-its-kind daily oral medication. • The drug is specifically indicated for adults suffering from advanced metastatic pancreatic ductal adenocarcinoma. • This approval is significant as it provides a novel, non-invasive treatment option for a highly aggressive form of cancer with limited therapeutic alternatives.

• The U.S. Food and Drug Administration (FDA) has approved a new daily pill developed by Revolution Medicines for the treatment of pancreatic cancer. • This groundbreaking medication introduces a novel therapeutic approach to combat one of the most lethal forms of cancer. • The approval is significant as it provides patients with a new targeted option for managing a disease known for its high mortality rate and limited treatment efficacy.

• The U.S. FDA has granted speedy approval to a groundbreaking pancreatic cancer drug developed by Revolution Medicines. • In a large-scale trial, the therapy demonstrated the ability to double the survival rate for patients suffering from advanced, metastatic disease. • The drug was one of the first to utilize a new expedited FDA review process, which reduces approval timelines from 10-12 months to just one or two months for urgent health priorities.

• The U.S. has approved daraxonrasib, a breakthrough drug designed to treat pancreatic cancer, which is widely regarded as one of the most serious and difficult-to-treat malignancies. • Unlike traditional chemotherapy, this medication specifically targets the activated KRAS protein found within pancreatic cancer cells to inhibit tumor growth. • Clinical trial data involving medical oncologist Kyaw Lwin Aung indicates that the drug is highly effective, doubling the survival time for patients.

• The FDA has approved a landmark drug designed to treat pancreatic cancer, one of the deadliest forms of the disease. • The medication utilizes a new therapeutic approach by blocking a specific protein that fuels tumor growth in the vast majority of pancreatic cancer cases. • This approval is significant because the drug has demonstrated a measurable ability to improve patient survival rates.

• The US Food and Drug Administration (FDA) has granted expedited approval to daraxonrasib, a first-of-a-kind oral medication designed to treat the most common form of pancreatic cancer. • Developed by Revolution Medicines, the drug functions as a Ras multiselective inhibitor, targeting specific genetic drivers of the disease. • This approval is significant because it provides patients with a more effective treatment option for one of the deadliest types of cancer, which often has limited therapeutic alternatives.

• Researchers analyzed the impact of the 21st Century Cures Act, which allows the FDA to approve novel drugs based on a single pivotal trial rather than multiple studies. • Findings indicate that since 2016, the number of studies supporting new drug approvals in the US has steadily decreased. • This shift reflects a trend toward increased FDA flexibility and a higher reliance on industry-funded data to accelerate the drug approval process.

FDA officials approve first-of-a-kind pill called daraxonrasib to fight one of the deadliest types of cancerThe US Food and Drug Administration (FDA) approved a groundbreaking new drug for the most common form of pancreatic cancer, offering US patients a more effective treatment against one of the deadliest types of the disease.FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases. It’s an approach that has eluded drugmakers for decades. Continue reading...

Triptorelin, already listed for prostate cancer, should have unrestricted use, the Pharmaceutical Benefits Advisory Committee saysGet our breaking news email, free app or daily news podcastThe federal government should fund treatment for thousands of women with breast cancer or endometriosis, and children with gender dysphoria, according to the Pharmaceutical Benefits Scheme’s advisory committee.The committee met urgently in July in response to AstraZeneca’s announcement it would remove Zoladex from the market, risking leaving more than 7,500 women with breast cancer without an alternative treatment. Continue reading...

• Early-stage research indicates that GLP-1 medications, including Ozempic, Wegovy, Zepbound, and Mounjaro, may reduce the risk of developing certain cancers. • Data shows that patients with liver, breast, colorectal, or lung cancer using these drugs were 38% to 50% less likely to progress to stage 4 disease. • Experts caution that current findings are based on observational studies, which analyze existing data and are less conclusive than controlled clinical trials.

Poolbeg Pharma to test the treatment in NHS hospitals and says it is also developing a GLP-1 weight loss pillA London-based startup is about to trial a drug at six NHS hospitals that could stop people on cancer immunotherapy getting a life-threatening side-effect.Poolbeg Pharma said its oral drug POLB 001 could make treatment for blood cancer safer by preventing cytokine release syndrome (CRS), when the immune system goes into overdrive and attacks the body, leading to organ damage. Continue reading...

The vital medicine, made by AstraZeneca, will not be available from November, possibly leaving thousands of women without treatmentGet our breaking news email, free app or daily news podcastThousands of women could be left without vital breast cancer and endometriosis medicine when AstraZeneca removes its treatment from the Pharmaceutical Benefits Scheme (PBS) and the private market, experts warn.Zoladex will no longer be available in Australia from November, as the ABC first reported, but some existing patients will still be able to access it for an additional six months. Continue reading...

Elahere is first new drug for chemotherapy-resistant ovarian cancer to be approved by NHS for 20 yearsHundreds of women with hard-to-treat ovarian cancer can now be offered a new life-prolonging treatment, after NHS England approved its introduction. It is the first new drug for resistant ovarian cancer to be approved for more than 20 years.Ovarian is the 18th most common type of cancer globally, affecting more than 300,000 women a year. More than three-quarters of patients are diagnosed at an advanced stage, making it harder to treat. Continue reading...

Durvalumab shows promising results in trial led by London-based Institute of Cancer ResearchDoctors are hailing a drug that spares bladder cancer patients “life-changing” surgery and stops tumours coming back.Bladder cancer is the ninth most common cancer in the world. Advanced or aggressive forms are often treated with surgery to remove the entire bladder, with patients left having to find alternative ways to pass urine for the rest of their life. Continue reading...

Experimental tablet produces encouraging results in patients with world’s most common forms of disease• ‘I was getting ready to say goodbye’: patient’s hope after smart drug successA smart drug that stops cancer cells “hiding” from treatment can shrink tumours by at least 30% in six of the world’s most common forms of the disease, early trial results show.While immunotherapy treatments have improved survival rates for many patients, their effectiveness can stall or fail when tumour cells hide and then spread. Continue reading...

Pat Brogan preparing to walk his daughter down the aisle after trial of treatment designed to stop disease from hiding• Smart drug that strips cancer cells of ‘invisibility cloak’ can shrink tumours by 30%, trial showsOne of the first patients to benefit from a pioneering smart drug that appears to melt away the “invisibility cloak” that can shield cancer cells from treatment is Pat Brogan, from Cowdenbeath, Scotland.The 68-year-old, whose tumours have shrunk by almost a third, is preparing to walk his daughter down the aisle this month and holiday in Spain with his wife, Linda – milestones he once feared he would never reach. Continue reading...

PhenMap tool could spare thousands of patients from treatment that would be ineffective for themA new AI-driven way of identifying how patients with advanced bowel cancer will respond to a drug that was recently introduced by the NHS has been announced.Researchers at London’s Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have developed the method with the goal of sparing potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. Continue reading...

Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drugGSK has revealed positive results for a treatment for gynaecological cancers as its chief executive, Luke Miels, steps up drug development efforts at the group.The company said that in an early-stage trial Mocertatug Rezetecan, known as Mo-Rez, shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer. Continue reading...

Relacorilant, typically used to treat Cushing’s syndrome, could improve outcomes in platinum-resistant casesA drug originally used to treat a rare disease could extend the lives of patients with an aggressive form of ovarian cancer, according to a clinical trial.Platinum-resistant ovarian cancer occurs when the disease progresses within six months of starting platinum-based chemotherapy. This form of chemotherapy is different from other types because it uses compounds that contain platinum to destroy cancer cells by preventing them from dividing. Continue reading...